Triplet Induction + 1 or 2-Drug Maintenance
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
Arms / Cohorts
Active Comparator:Arm I: Bortezomib + Lenalidomide + Dexamethasone + Lenalidomide Maintenance
Accepting patients
Experimental:Arm II: Daratumumab + Lenalidomide + Dexamethasone + Lenalidomide Maintenance
Accepting patients
Experimental:Arm III: Daratumumab + Lenalidomide + Dexamethasone + Daratumumab and Lenalidomide Maintenance
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.